专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014084568A1 TOPICAL GEL COMPOSITION CONTAINING DEXIBUPROFEN EMULSION WITH ENHANCED PERMEABILITY 审中-公开
标题翻译：含有DEXIBUPROFEN乳液的局部凝胶组合物具有增强渗透性
公开(公告)号：WO2014084568A1
公开(公告)日：2014-06-05
申请号：PCT/KR2013/010786
申请日：2013-11-26
申请人： DONG-A ST CO.,LTD
发明人： KIM, Soon-Hoe , SON, Mi-Won , JANG, Sun-Woo , JIN, Sung-Giu , DO, Eui-Seon , HAN, Sang-Dug , PARK, Chan-Woong , KANG, Myung-Joo
IPC分类号： A61K31/192 , A61K9/06 , A61K47/30
CPC分类号： A61K47/10 , A61K9/0014 , A61K9/06 , A61K31/192 , A61K47/14 , A61K47/26 , A61K47/32
摘要： The present invention provides an emulsion gel composition of dexibuprofen, with clear pharmacological activity without needing to be metabolized or otherwise processed, wherein the dexibuprofen is finely dispersed in the gel carrier while dissolved in the emulsion and cosolvent. The present invention provides a fine gel formulation of dexibuprofen, a poorly water-soluble drug, enabling enhanced skin absorption of dexibuprofen and reduced content of alcoholic solvent and thus minimizing skin irritation. Moreover, the fine droplets allow for a pleasant feeling when applied to the skin.
摘要翻译：本发明提供了一种具有明显的药理活性而不需要代谢或以其它方式加工的右旋布洛芬的乳液凝胶组合物，其中，当溶解在乳液和助溶剂中时，将解联苯丙酮细分散在凝胶载体中。本发明提供了一种精细的凝胶配方，即一种难溶于水的药物dexibuprofen，能够增强皮肤吸收去甲苯磺酸和降低酒精溶剂含量，从而最大限度地减少皮肤刺激。此外，细小的液滴允许在施用于皮肤时具有愉快的感觉。

2. 发明申请

WO2014035064A1 THE NOVEL TENOFOVIR DISOPROXIL SALT AND THE PREPARATION METHOD THEREOF 审中-公开
标题翻译：新型硝酸盐脱盐酸盐及其制备方法
公开(公告)号：WO2014035064A1
公开(公告)日：2014-03-06
申请号：PCT/KR2013/006845
申请日：2013-07-30
申请人： CHONG KUN DANG HOLDINGS CORP.
发明人： RYU, Ho-Hyung , WOO, Dae-Koo , KANG, Sung-Kwon , CHON, Mi-Hee , PARK, Dae-Jong , LEE, Su-Kyoung , CHOI, Sul-Ji
IPC分类号： C07D473/34 , C07F9/02 , A61K31/52 , A61P31/18
CPC分类号： C07F9/65616
摘要： The present invention relates to a novel tenofovir disoproxil aspartate compound. The aforementioned salt compound allows minimal formation of related substances occurring with passage of time, increasing the stability of the formulation by drastically reducing the formation of impurities during storage. Also, the need for a separate study of toxicological effects is eliminated. Moreover, the salt compound of the present invention possesses superior physicochemical properties, with a significant improvement in stability, hygroscopicity, and solubility, thereby allowing it to be used as an active ingredient along with pharmaceutically acceptable carriers for a pharmaceutical composition for the treatment of HIV infection and chronic hepatitis B.
摘要翻译：本发明涉及一种新型替诺福韦替夫洛尔天冬氨酸酯化合物。上述盐化合物允许随时间流逝发生相关物质的最小形成，通过在储存期间大大减少杂质的形成来提高制剂的稳定性。此外，消除了对毒理学影响的单独研究的需要。此外，本发明的盐化合物具有优异的物理化学性质，其稳定性，吸湿性和溶解性显着提高，从而允许其与用于治疗HIV的药物组合物的药学上可接受的载体一起用作活性成分感染和慢性乙型肝炎

3. 发明申请

WO2013133647A1 STABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND HYALURONIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND THE MANUFACTURING METHOD THEREOF 审中-公开
标题翻译：含有吡罗昔康或其药学上可接受的盐和羟丙酸或其药学上可接受的盐的稳定的液体药物组合物及其制备方法
公开(公告)号：WO2013133647A1
公开(公告)日：2013-09-12
申请号：PCT/KR2013/001856
申请日：2013-03-07
申请人： DONG-A ST CO., LTD.
发明人： KIM, Soon-Hoe , SON, Mi-Won , JANG, Sun-Woo , KANG, Myung-Joo , MA, Kyung-Wan
IPC分类号： A61K31/54 , A61K31/728 , A61P29/00 , A61P25/00
CPC分类号： A61K47/40 , A61K9/0019 , A61K31/5415 , A61K31/728 , A61K47/10 , A61K2300/00
摘要： The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and β-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof. Therefore, the novel composition and the formulation method thereof provided by the present invention may be used to produce a liquid injection composition of piroxicam and hyaluronic acid.
摘要翻译：本发明涉及由吡罗昔康或其药学上可接受的盐（非类固醇抗炎药）和透明质酸或其药学上可接受的盐（用于治疗退行性关节炎）组成的新型液体组合物。具体地说，本发明提供高度物理化学稳定的液体注射剂，其包含作为活性成分的吡罗昔康和透明质酸，以及β-环糊精或其衍生物和聚乙二醇作为添加剂，以增强其物理化学稳定性及其制备方法。因此，本发明提供的新型组合物及其制备方法可用于制备吡罗昔康和透明质酸的液体注射组合物。

4. 发明申请

WO2012134126A2 USE OF COMPOUNDS ISOLATED FROM MORUS BARK 审中-公开
标题翻译：使用从MORUS BARK分离的化合物
公开(公告)号：WO2012134126A2
公开(公告)日：2012-10-04
申请号：PCT/KR2012/002162
申请日：2012-03-26
申请人： DONG WHA PHARM. CO., LTD. , CHANG, Hwan-Bong , YOON, Joo-Byoung , LEE, Hyun-Yong , CHOI, Hyun-Sik , LEE, Hyung-Bok
发明人： CHANG, Hwan-Bong , YOON, Joo-Byoung , LEE, Hyun-Yong , CHOI, Hyun-Sik , LEE, Hyung-Bok
IPC分类号： A61K31/353
CPC分类号： A61K31/352 , A23L33/10 , A61K31/05 , A61K31/353
摘要： The present invention provides an AGE inhibitor and a health functional food for inhibiting an occurrence of diabetic complications. Particularly, the present invention comprises a compound selected from the group consisting of mulberrofuran G, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2`,4`,5,7-tetrahydroxyflavanone, morusignin L and dihydromorin isolated from Morus Bark as an active ingredient. The compounds disclosed above inhibit the production of AGE which is a causative substance of diabetic complications. Thus, the compounds could be used as an AGE inhibitor and a health functional food for inhibiting diabetic nephropathy, diabetic retinopathy and diabetic neuropathy.
摘要翻译：本发明提供了AGE抑制剂和用于抑制糖尿病并发症发生的健康功能性食品。特别地，本发明包括选自以下的化合物：由桑树呋喃G，呋喃孢子K，库布宁G，奎宁酮Z，氧基维生素，2'，4'，5,7-四羟基黄烷酮，morusignin L和从Morus Bark分离的二氢肌醇有效成分。上述公开的化合物抑制作为糖尿病并发症的病因的AGE的产生。因此，该化合物可用作AGE抑制剂和用于抑制糖尿病性肾病，糖尿病性视网膜病变和糖尿病性神经病变的健康功能食品。

5. 发明申请

WO2012124887A2 COMPOSITION COMPRISING THE EXTRACT OF HERBS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译：包含用于预防或治疗神经退行性疾病的草药提取物的组合物
公开(公告)号：WO2012124887A2
公开(公告)日：2012-09-20
申请号：PCT/KR2011/010290
申请日：2011-12-29
申请人： DONG-A PHARM.CO.,LTD. , KIM, Soon-Hoe , SON, Mi-Won , CHOI, Sang-Zin , KIM, Hye-Ju , RYU, Ja-Young , KIM, Sun-Yeou
发明人： KIM, Soon-Hoe , SON, Mi-Won , CHOI, Sang-Zin , KIM, Hye-Ju , RYU, Ja-Young , KIM, Sun-Yeou
IPC分类号： A61K36/8945 , A61P25/28 , A61P25/16
CPC分类号： A61K36/8945 , A23L2/52 , A23L33/105 , A23V2002/00 , A61K9/0019 , A61K9/08 , A61K9/20 , A61K9/48 , A61K2236/15 , A61K2236/333 , A61K2236/51 , A61K2236/53
摘要： This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.
摘要翻译：本发明涉及用于预防或改善神经变性疾病的药物组合物和保健功能食品，其包含重量比为3.5:1（w / w）的薯mixed药材和薯Di药材的混合草药提取物。本发明提取的混杂薯Rh药材与薯ni药材按3.5：1的比例配伍，对增加体内神经生长因子的数量，增加神经细胞增殖，促进神经炎的形成，增强认知能力具有协同作用。因此，本发明的草药提取物可以用于预防或治疗神经变性疾病的药物组合物和保健功能食品。

6. 发明申请

WO2007069838A1 A MANUFACTURING PROCESS OF 2',2'-DIFLUORONUCLEOSIDE AND INTERMEDIATE 审中-公开
标题翻译： 2'，2'-二氟硼烷和中间体的制造方法
公开(公告)号：WO2007069838A1
公开(公告)日：2007-06-21
申请号：PCT/KR2006/005372
申请日：2006-12-11
申请人： DONG-A PHARM.CO., LTD. , KIM, Moon-Sung , KIM, Yong-Jik , CHOI, Jun-Ho , LIM, Hong-Gyu , CHA, Dae-Won
发明人： KIM, Moon-Sung , KIM, Yong-Jik , CHOI, Jun-Ho , LIM, Hong-Gyu , CHA, Dae-Won
IPC分类号： C07D307/32
CPC分类号： C07D307/33 , C07D307/20 , C07D405/04 , C07H19/06 , Y02P20/55
摘要： The present invention relates to more improved process for preparing 2'-deoxy-2',2'-difluoronucleoside and its intermediate. The present invention provide a process for preparing an erythro enantiomer in greater than 98% purity, comprising forming a lactone ring by hydrolyzing ethyl (3RS )-2,2-difluoro-3-hydroxy-3-(2,2-dimethyloxolan-4-yl)propionate is hydrolyzed in the presence of hydrolysis reagents selected from acetic acid or chloroacetic acid, water and a mixture of organic solvents selected from the group comprising acetonitrile, dioxane, tetrahydrofuran or toluene, in¬ troducing a substituted benzoyl protecting group at the 3-position and 5-position, and recrys- tallizing said erythro enantiomer. Further, the present invention provides a process for selectively preparing, in greater than 99% purity, a beta-anomer 2'-deoxy-2',2'-difluoronucleoside at the 3'-position and 5'-position that are protected by a substituted benzoyl in a 2:3 alpha/beta anomeric ratio.
摘要翻译：本发明涉及制备2'-脱氧-2'，2'-二氟核苷及其中间体的更加改进的方法。本发明提供制备纯度高于98％的赤式对映异构体的方法，包括通过水解（3RS）-2,2-二氟-3-羟基-3-（2,2-二甲基氧基-4- - 基）丙酸酯在选自乙酸或氯乙酸的水解试剂，水和选自乙腈，二恶烷，四氢呋喃或甲苯的有机溶剂的混合物存在下水解，在该溶剂中引入取代的苯甲酰基保护基 3位和5位，并重新显示所述红色对映异构体。此外，本发明提供了在大于99％的纯度中选择性地制备在3'-位和5'-位上的β-端基异构体2'-脱氧-2'，2'-二氟核苷的方法，其被 2：3α/β端基异构体取代的苯甲酰基。

7. 发明申请

WO2006085723A1 THE ENTERIC COATED PHARMACEUTICAL ORAL FORMULATIONS COMPRISING ACID-LABILE ACTIVE SUBSTANCES, AND A METHOD THEREOF 审中-公开
标题翻译：包含酸可活化物质的肠包衣药物口服制剂及其方法
公开(公告)号：WO2006085723A1
公开(公告)日：2006-08-17
申请号：PCT/KR2006/000459
申请日：2006-02-08
申请人： GL PHARMTECH CORP. , SONG, Woo Heon , WANG, Hun Sik , KWON, Min Chang , PARK, Jun Sang
发明人： SONG, Woo Heon , WANG, Hun Sik , KWON, Min Chang , PARK, Jun Sang
IPC分类号： A61K9/28
CPC分类号： A61K9/2846
摘要： This invention relates to an oral pharmaceutical formulation formed by a direct coating of an enteric layer containing polyethylene glycol as a plasticizer on a core containing an acid-labile pantoprazole, and its manufacturing method. The enteric-coated oral pharmaceutical formulation of this invention, which combines directly a core containing an acid-labile pantoprazole and an enteric layer in the absence of an inert intermediate layer, is able to improve the storage stability of the acid-labile pantoprazole and maximize the bioavailability and oral absorption rates via preventing related substances from increasing.
摘要翻译：本发明涉及通过在包含酸不稳定泮托拉唑的核心上直接包衣含有聚乙二醇作为增塑剂的肠溶层形成的口服药物制剂及其制造方法。本发明的肠溶包衣口服药物制剂在不存在惰性中间层的情况下直接结合含有酸不稳定泮托拉唑和肠溶层的核心能够提高酸不稳定泮托拉唑的储存稳定性，通过防止相关物质增加的生物利用度和口服吸收率。

8. 发明申请

WO2005004848A1 THE SOLID DISPERSION OF TACROLIMUS 审中-公开
标题翻译：固体分散剂
公开(公告)号：WO2005004848A1
公开(公告)日：2005-01-20
申请号：PCT/KR2004/001684
申请日：2004-07-09
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee-Jong , LIM, Jong-Lae , KI, Min-Hyo , YUN, Ji-Hun
发明人： SHIN, Hee-Jong , LIM, Jong-Lae , KI, Min-Hyo , YUN, Ji-Hun
IPC分类号： A61K9/14
CPC分类号： A61K9/145 , A61K9/1617 , A61K9/1676 , A61K31/4523 , A61K38/13
摘要： The present invention relates to the carrier of the solid dispersion of tacrolimus, which is prepared by using the solid surfactant having a property of HLB value higher than or equal to about 7. The surfactants carry out a function of a carrier and a function of a dissolution enhancer, simultaneously. As a result, the dissolution rate of tacrolimus is improved, and the oral absorbability and the bioavailability may be increased due to rapid drug release.
摘要翻译：本发明涉及通过使用具有HLB值高于或等于约7的性质的固体表面活性剂制备的他克莫司的固体分散体的载体。表面活性剂具有载体的功能和作用溶解增强剂，同时。结果，他克莫司的溶出速度提高，口服吸收性和生物利用度可能由于快速的药物释放而增加。

9. 发明申请

WO2023033557A1 PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE 审中-公开
公开(公告)号：WO2023033557A1
公开(公告)日：2023-03-09
申请号：PCT/KR2022/013084
申请日：2022-09-01
申请人： DONG-A ST CO., LTD.
发明人： JANG, Sun-Woo , SHIN, Chang-Yell , KIM, Hae-Sun , HYUN, Sang-Min , KIM, Yong-Jik , SHIN, Chang-Yong , KIM, Jae-Han
IPC分类号： A61K9/70 , A61K47/14 , A61K31/13 , A61P25/28
摘要： The present invention provides a percutaneous absorption preparation for the treatment of dementia, comprising a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer comprises memantine enanthate, a solubilizer, and a pressure-sensitive adhesive. The percutaneous absorption preparation for the treatment of dementia according to the present invention does not form crystal precipitation, shows high skin permeability, allows easy clinical control of the usable patch area, and allows control of the absorption rate by adjusting the rate of release, thus minimizing skin irritation, and provides an economic benefit of minimal waste of the drug while also preventing overdose of the drug.

10. 发明申请

WO2014200211A1 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM AND HYALURONIC ACID FOR THE TREATMENT OF OSTEOARTHRITIS 审中-公开
标题翻译：含有PIROXICAM和HYALURONIC酸的液体药物组合物用于治疗OSTEOARTHRITIS
公开(公告)号：WO2014200211A1
公开(公告)日：2014-12-18
申请号：PCT/KR2014/004745
申请日：2014-05-27
申请人： DONG-A ST CO., LTD
发明人： KIM, Soon-Hoe , SON, Mi-Won , JANG, Sun-Woo , PARK, Chan-Woong , MA, Kyung-Wan , JUNG, Sang-Won
IPC分类号： A61K31/54 , A61K31/728 , A61P19/02 , A61P19/00
CPC分类号： A61K31/728 , A61K9/0019 , A61K31/5415 , A61K47/02 , A61K2300/00
摘要： The present invention relates to the pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio that generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The present invention provides a pharmaceutical composition for the treatment of osteoarthritis comprising 0.25-10.0 wt% of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt% of hyaluronic acid or its pharmaceutically acceptable salt, where the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3. The liquid pharmaceutical composition according to the present invention has an outstanding therapeutic effect simultaneously on both inflammation and pain, thus providing an injectable formulation for intra-articular injection with synergistic effect on the treatment of osteoarthritis.
摘要翻译：本发明涉及用于治疗骨关节炎的药物组合物，其包含吡罗昔康或其药学上可接受的盐和透明质酸或其药学上可接受的盐，其特定比例同时产生对抗炎和镇痛作用的协同作用。本发明提供了用于治疗骨关节炎的药物组合物，其包含0.25-10.0重量％的吡罗昔康或其药学上可接受的盐和0.5-5.0重量％的透明质酸或其药学上可接受的盐，其中，炎痛喜酸或其药学上可接受的盐的重量比盐和透明质酸或其药学上可接受的盐在1:1至1:3之间。根据本发明的液体药物组合物在炎症和疼痛方面同时具有突出的治疗效果，因此提供关节内注射的可注射制剂，对治疗骨关节炎具有协同作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式